Home | Articles
Published on:October 2020
Indian Journal of Pharmaceutical Education and Research, 2020; 54(3s):s457-sS463
Review Article | doi:10.5530/ijper.54.3s.144

COVID-19 Vaccine Development, Trials and Tribulations


Authors and affiliation (s):

Juny Sebastian1, Mandyam Dhati Ravi2, Tegginamat Pramod Kumar3,*

1Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, S S Nagara, Mysuru, Karnataka, INDIA.

2Department of Pediatrics, JSS Medical College and Hospital, JSS Academy of Higher Education and Research, S S Nagara, Mysuru, INDIA.

3Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, S S Nagara, Mysuru, Karnataka, INDIA.

Abstract:

The coronavirus disease 19 (COVID-19) is a pandemic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, COVID-19 has affected 210 countries and territories around the world. But there is no clinically approved antiviral drug or vaccine against COVID-19. Governments, private manufactures, academic institutions and non-profit organizations are working hard at a breakneck pace to develop a vaccine for COVID-19. However, vaccine development is very lengthy and expensive process, typically takes many years to produce a licensed vaccine. Because of the high failure rates and cost factors, developers generally follow a linear development sequence with multiple pauses for analysis of data. But in view of the COVID-19 pandemic, development steps need to be executed parallel before confirming the outcome of the previous step. In the current review, we summarize the process involved in the COVID-19 vaccine development and its challenges.

Key words: Candidate Vaccine, Corona Virus, COVID-19 Vaccine, SARS-CoV-2, Vaccine Clinical Trial, Vaccine Development.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).

 

Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs